US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Verrica Pharmaceuticals Inc. - Common Stock
(NQ:
VRCA
)
4.380
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verrica Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
This Tractor Supply Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
↗
October 03, 2024
Via
Benzinga
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
October 02, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
September 13, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
September 04, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
↗
August 27, 2024
Via
Benzinga
Crude Oil Down Over 1%; Mercury Systems Shares Spike Higher
↗
August 14, 2024
Via
Benzinga
Dow Jumps Over 200 Points; Performance Food Group Shares Gain After Q4 Results
↗
August 14, 2024
Via
Benzinga
Topics
Stocks
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
↗
August 14, 2024
VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
US Stocks Mixed; Inflation Rate Falls More Than Projected
↗
August 14, 2024
Via
Benzinga
Topics
Economy
Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
↗
August 14, 2024
Verrica Pharmaceuticals shares positive preliminary results from Part 2 of its Phase 2 trial for VP-315 in treating basal cell carcinoma, showing promising tumor reduction and safety. No serious...
Via
Benzinga
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 14, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
August 14, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
August 06, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
7 Short-Squeeze Stocks That Could Beat Down the Bears
↗
July 15, 2024
Panic can be a cruel emotion, especially when the consequences are uncapped red ink.
Via
InvestorPlace
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
July 01, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
May 30, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 26, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
May 15, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
May 14, 2024
Via
Benzinga
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
↗
May 13, 2024
VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
May 13, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
May 09, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
May 08, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
March 26, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
March 08, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
